I think the lesson from todays presentation by Dr. Liau is that technical presentations that are telling us essentially what we already know are not going to move the stock up. Investors and potential investors are not looking for more of what they already know, they're looking for advancements from the company. The MIA may be the first of them, unless we're surprised by something else, but as good as what people like Dr. Liau and Ashkan is telling us, it is known. Perhaps a formal report on the newer trials being done at UCLA and elsewhere might have a little additional impact, but again we know the outcome of using Keytruda, and other products, with our vaccine improves the results dramatically, but only if used with the vaccine.
Would there be any difference if Dr. Liau's presentation were made at a major conference like ASCO, AACR, SNO, etc. I really tend to doubt it if nothing significantly different was seen in the conference. Personally I'm still not satisfied with the lack of support for what had been said about the Top 100 in the trial, I've still not seen data presented that proved that 50 or more were living beyond 7 years, and today that probably should be beyond 8 years, but it's just not been discussed. I don't know that it would make that much difference, the real benefit is add Keytruda, etc. and suddenly half the people or more are living 5 years or longer, and the odds are good that most who live 5 will live their normal lifespan. That's the real news that people need to be hearing about using the vaccine, and that it may do the same thing in other equally deadly other solid cancers.
I'm sure that there are cancers where cures are occurring in 70 to 80% of patients, there we may find that we can halve the number who aren't being cured, that would still be huge news, news that's worthy of all receiving the vaccine as long as it's impossible to identify those who won't be cured up front. To prove such a benefit would probably require very large trials for extensive periods of time, but if the vaccine's demonstrated to benefit far deadlier solid cancers, like pancreatic, it's use should be accepted in others without massive additional trials being run.
Tomorrow the CEO of IMGN happens to be presenting at a brokers conference, I doubt it will make much difference unless he has something new to say, primarily because he has done many similar presentations. I believe it would be very different if it were L.P. making the presentation for NWBO because she's done no such presentations so everything she says will be new to many investors. I believe it's this sort of presentation that is needed now and it's up to the company to do it, not for the clinicians to present the same information to new audiences of scientists and Drs. I've got to believe that thousands of Doctors are waiting for only one thing, the ability to order DCVax-L for their patients, until that happens they wait, and their patients die.
Gary
